|
KMID : 0939920170490020387
|
|
대한암학회지
2017 Volume.49 No. 2 p.387 ~ p.398
|
|
|
Underexpression of HOXA11 Is Associated with Treatment Resistance and Poor Prognosis in Glioblastoma
|
|
Se Young-Bem
Kim Seung-Hyun
Kim Ji-Young
Kim Ja-Eun
Dho Yun-Sik
Kim Jin-Wook
Kim Yong-Hwy
Woo Hyun-Goo
Kim Se-Hyuk
Kang Shin-Hyuk
Kim Hak-Jae
Kim Tae-MIn
Lee Soon-Tae
Choi Seung-Hong
Park Sung-Hye
Kim Il-Han
Kim Dong-Gyu
Park Chul-Kee
|
|
|
Abstract
|
|
|
Purpose: Homeobox (HOX) genes are essential developmental regulators that should normally be in the silenced state in an adult brain. The aberrant expression of HOX genes has been associated with the prognosis of many cancer types, including glioblastoma (GBM). This study examined the identity and role of HOX genes affecting GBM prognosis and treatment resistance.
Materials and Methods: The full series of HOX genes of five pairs of initial and recurrent human GBM samples were screened by microarray analysis to determine the most plausible candidate responsible for GBM prognosis. Another 20 newly diagnosed GBM samples were used for prognostic validation. In vitro experiments were performed to confirm the role of HOX in treatment resistance. Mediators involved in HOX gene regulation were searched using differentially expressed gene analysis, gene set enrichment tests, and network analysis.
Results: The underexpression of HOXA11 was identified as a consistent signature for a poor prognosis among the HOX genes. The overall survival of the GBM patients indicated a significantly favorable prognosis in patients with high HOXA11 expression (31±15.3 months) compared to the prognoses in thosewith low HOXA11 expression (18±7.3 months, p=0.03). When HOXA11 was suppressed in the GBM cell lines, the anticancer effect of radiotherapy and/or temozolomide declined. In addition, five candidate mediators (TGFBR2, CRIM1, TXNIP, DPYSL2, and CRMP1) that may confer an oncologic effect after HOXA11 suppression were identified.
Conclusion: The treatment resistance induced by the underexpression of HOXA11 can contribute to a poor prognosis in GBM. Further investigation will be needed to confirm the value of HOXA11 as a potential target for overcoming the treatment resistance by developing chemo- or radiosensitizers.
|
|
|
KEYWORD
|
|
|
Homeobox genes, HOXA11, Glioblastoma, Treatment resistance
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|